Explore
Search ClinicalTrials.gov
Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.
Results for “Novartis”
- Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI PatientsRecruiting
Sponsor: Novartis Pharmaceuticals
Myocardial Infarction
Russia
Sponsor: Novartis Pharmaceuticals
Immunoglobulin A Nephropathy (IgAN)
United States, Brazil, China, Czechia, Germany +6 more
Sponsor: Novartis Pharmaceuticals
Breast Cancer
Russia
Sponsor: Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
United States, Argentina, Australia, Belgium, Brazil +14 more
Sponsor: Novartis Pharmaceuticals
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
United States, Puerto Rico
- The Mycophenolate Pregnancy RegistryRecruiting
Sponsor: Genentech, Inc.
Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases
United States
- A Study of DII235 in Adults With Elevated Lipoprotein(a)Active Not Recruiting
Sponsor: Novartis Pharmaceuticals
Lipoprotein Disorder
United States, China, Germany, Japan
Sponsor: Novartis Pharmaceuticals
Berger Disease · Bergers Disease · IgA Nephropathy · Immunoglobulin A Nephropathy
United States, China, Japan, South Korea
Sponsor: Novartis Pharmaceuticals
Juvenile Idiopathic Arthritis
Sponsor: Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
Germany
Sponsor: Novartis Pharmaceuticals
C3 Glomerulopathy · Immune-complex-membranoproliferative Glomerulonephritis
United States, Argentina, Brazil, Canada, China +12 more
- PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADTNot Yet Recruiting
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
High-Risk Localized Prostate Cancer
United States
Sponsor: Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease (ASCVD)
United States, China, France, Germany, Hong Kong +6 more
- 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate CancerActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Prostatic Neoplasms
United States, Austria, Belgium, Canada, Czechia +9 more
Sponsor: Novartis Pharmaceuticals
Atypical Hemolytic Uremic Syndrome
United States, Brazil, China, Czechia, India +3 more
- Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE StudyActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Atherosclerotic Vascular Disease · Heterozygous Familial Hypercholesterolemia
Spain
Sponsor: Novartis Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria (PNH)
United States, Brazil, Colombia, Germany, Italy +1 more
- Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal HemoglobinuriaActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria
United States, Brazil, China, Czechia, France +12 more
Sponsor: Fred Hutchinson Cancer Center
Castration-Resistant Prostate Carcinoma · Metastatic Prostate Adenocarcinoma · Stage IVB Prostate Cancer AJCC v8
United States
- A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) PeriodNot Yet Recruiting
Sponsor: Novartis Pharmaceuticals
VEXAS Syndrome
- Specified Drug-use Survey of Leqvio for s.c. Injection.Active Not Recruiting
Sponsor: Novartis Pharmaceuticals
Familial Hypercholesterolaemia · Hypercholesterolaemia
Japan
Sponsor: Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
Australia, France, Germany, Italy, Spain +1 more
Sponsor: University Hospital, Clermont-Ferrand
Malnutrition · Esophageal Cancer · Head and Neck Cancer
France
Sponsor: Novartis Pharmaceuticals
Oligometastatic Prostate Cancer (OMPC)
United States, Argentina, Australia, Austria, Belgium +22 more
Sponsor: Novartis Pharmaceuticals
Multiple Sclerosis
United States